Chronic Lymphocytic Leukemia Excellence Forum

Chronic Lymphocytic Leukemia

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Podcasts

Dr Burger Discusses Outcomes Following RESONATE-2 and iLLUMINATE Studies

12/17/2020

Jan A. Burger, MD, PhD, MD Anderson Cancer Center, discusses "Outcomes of First-Line Ibrutinib in Patients with CLL/SLL and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and...

Jan A. Burger, MD, PhD, MD...

12/17/2020

Oncology

Interview

Real-World Outcomes of First-Line Ibrutinib vs CIT for CLL

12/16/2020

Lori Leslie, MD, discusses clinical outcomes among real-world patients with CLL given first-line therapy with ibrutinib or chemoimmunotherapy (CIT).

Lori Leslie, MD, discusses...

12/16/2020

Oncology

Videos

Anthony Mato, MD, Talks Real-World Biomarker Testing for CLL, SLL

12/09/2020

Dr Mato discusses real-world prognostic biomarker testing, treatment patterns and dosing among patients with CLL/SLL.

Dr Mato discusses real-world...

12/09/2020

Oncology

Videos

Othman Al-Sawaf, MD, Discusses Results From the Phase 3 CLL14 Trial

12/07/2020

Othman Al-Sawaf, MD, University Hospital of Cologne, Germany, discusses highlights from the phase 3 CLL14 trial, which looked at venetoclax plus obinutuzumab therapy for chronic lymphocytic leukemia (CLL). These data were presented at the...

Othman Al-Sawaf, MD, University...

12/07/2020

Oncology

Videos

John Allan, MD, Talks Long-Term Efficacy of First-Line Ibrutinib for TP53-Mutated CLL

12/07/2020

In this video, John Allan, MD, Weill Cornell Medicine, discusses long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukemia with 4 years of follow-up in patients with TP53 aberrations.

In this video, John Allan, MD,...

12/07/2020

Oncology

Podcasts

Episode 2: BTK Inhibitors for CLL and Lymphomas

07/03/2020

On this episode of Blood Bytes, John Leonard, MD, and Richard Furman, MD, discuss BTK inhibitors for the treatment of CLL and lymphomas.

On this episode of Blood Bytes,...

07/03/2020

Oncology

Videos

Venetoclax Monotherapy Yields Deep Responses, Manageable Safety in CLL

06/29/2020

Arnon P. Kater, MD, PhD, discusses results from the phase 3b VENICE I trial, which evaluated the efficacy of venetoclax in patients with relapsed/refractory CLL.

Arnon P. Kater, MD, PhD,...

06/29/2020

Oncology

Videos

Ibrutinib Plus Venetoclax Yields High Rates of Undetectable MRD in CLL

06/22/2020

Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, discusses the results of the MRD cohort of the CAPTIVATE trial, a multicenter phase 2 trial evaluating ibrutinib plus venetoclax in CLL and SLL.

Constantine Tam, MBBS (Hons),...

06/22/2020

Oncology

$Acalabrutinib Demonstrates Favorable Safety and Efficacy in Relapsed/Refractory CLL$

Videos

Acalabrutinib Demonstrates Favorable Safety and Efficacy in Relapsed/Refractory CLL

06/17/2020

Paolo Ghia, MD, PhD, discusses the results from the ASCEND study, which compared acalabrutinib monotherapy to physician’s choice of therapy in patients with relapsed or refractory CLL.

Paolo Ghia, MD, PhD, discusses...

06/17/2020

Oncology

Interview

Neil Kay, MD, Discusses Ibrutinib–Rituximab Combo for CLL, SLL

05/26/2020

Dr Kay discusses the recent expanded approval of ibrutinib in combination with rituximab for the treatment of patients with CLL and SLL.

Dr Kay discusses the recent...

05/26/2020

Oncology

Chronic Lymphocytic Leukemia Excellence Forum

Specialties

Events

Year Round Education

HMP Global Products